CAC2 Childhood Cancer Community News Digest (June 24-30)

Assorted News from the Last Week:

AWS is providing $10 million to accelerate research for pediatric health care and to better understand rare diseases, including $1 million to the Children’s Brain Tumor Network.

Novartis announced that the U.S. Food and Drug Administration (FDA) approved Lutathera for the treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NETs) for pediatric patients.

JAMA Pediatrics explores the important role that patient advocates play in pediatric oncology. Abstract (will post full article when available).

A Children’s Oncology Group study concluded that adding the mTOR inhibitor temsirolimus (Torisel) to chemotherapy in the first-line setting failed to improve event-free survival (EFS) among young patients with intermediate-risk rhabdomyosarcoma.

Young women (ages 15-39) who survived cervical cancer and leukemia were less likely to give birth and, when they did, sustained greater risk of serious obstetric complications, according to results from a retrospective cohort study.

SELLAS announces U.S. FDA rare pediatric disease designation was granted to SLS009 for the treatment of pediatric acute lymphoblastic leukemia.

Standardized surveillance identifies new tumors among children with a wide spectrum of cancer predisposition syndromes (CPSs), according to a study published online June 20 in JAMA Oncology.

The U.S. Food and Drug Administration (FDA) has granted accelerated approval to repotrectinib (Augtyro) for adult and pediatric patients aged 12 years or older with solid tumors that are locally advanced, metastatic, or ineligible for surgical removal; have progressed after prior treatment or have no other available treatment options; and harbor NTRK gene fusions.

Upcoming Webinars, Online Opportunities, and Meetings:

56th Congress of the International Society of Paediatric Oncology (SIOP 2024), which will take place in Honolulu, Hawaii, USA | October 17-20, 2024. Registration is open and anyone who registers before July 17, 2024 can take advantage of the discounted rates.

Past Recordings

National Council of Research Advocates met on June 26. The videocast and speaker slides can be found here.

A conversation with Day One Biopharmaceuticals CEO Jeremy Bender on building a strategy for pediatric cancer therapies that serves both patients and investors.

CAC2 member Mark Levine hosts a podcast called, “Help and Hope Happen Here” (available on Apple Podcasts, Spotify, and Google Podcasts). Access recent podcasts with CAC2 Members (and visit Help and Hope Happen Here for interviews with other CAC2 members and thought leaders from around the community):

Take Action:

Try out the monthly donation platform dedicated to childhood cancer that helps nonprofits and warrior-parents team up to raise money for research, family support, and advocacy offered at no charge by Hello Cure. 

CAC2 Member the Children’s Cancer Cause announced that the organization is accepting applications for its 2024 Survivorship Champion’s Prize. This $10,000 annual award is presented to a group, program or institution making significant advances in programs and services to provide life-long health maintenance for survivors of pediatric cancers.

CAC2 Student Member Na Ouyang, MSN, RN (PhD candidate, Yale School of Nursing) is conducting her dissertation study, which focuses on exploring how clinician-parent communication influences parents’ preparation for their child’s end-of-life and then impacts parental grief in early bereavement. Click here for information and details.  Click here for the IRB Approval document.

CAC2 Innovation Council Recommendation: ArtVsCancer

Overview of the Opportunity: ArtVsCancer is a public Facebook group where AI artists create free custom art for childhood cancer patients and other children with life threatening diseases.

The Requester: Arthur van Vugt, Dutch childhood psychologist

The Type of Request: Information Sharing

The Ask: Inform parents about the existence of the group

Supporting Documentation:


Sign up to receive a copy of CAC2's free childhood cancer news digest in your inbox each week.

This field is for validation purposes and should be left unchanged.